Results 261 to 270 of about 10,746,438 (360)

Anti‐Inflammatory, Antioxidant, Molecular Docking and Pharmacokinetics Properties of Cycloeucalenone Isolated From Musa × paradisiaca L. Fruit Peels

open access: yesChemistry &Biodiversity, Volume 23, Issue 1, January 2026.
ABSTRACT This study isolated a compound with anti‐inflammatory properties from Musa × paradisiaca fruit peels. The methanol extract was partitioned, and the hexane fraction with the best bioactivity was subjected to column chromatography before characterization via Fourier transform infrared (FTIR), UV–visible (UV–VIS) and NMR analysis.
Ibeabuchi J. Ali   +7 more
wiley   +1 more source

Association between sickle cell anaemia and dental caries among children in Nigeria. [PDF]

open access: yesBMC Oral Health
Afolabi JB   +5 more
europepmc   +1 more source

Human Protein Z as the Second Known Heme‐Binding Protein from the Endogenous Blood Coagulation Inhibitor System

open access: yesChemBioChem, Volume 27, Issue 1, January 2026.
Protein Z is a vitamin K‐dependent anticoagulant with elusive molecular functions. Herein, it is shown that heme binds to protein Z and induces conformational changes. One histidine‐based heme‐binding motif is identified. High heme‐binding affinity and functional effects are demonstrated on protein level. These findings shed new light on the structural
Paula Lindemann, Marie‐T. Hopp
wiley   +1 more source

Burden of sickle cell anemia in Africa: A systematic review and meta-analysis. [PDF]

open access: yesPLoS One
Jonani B   +9 more
europepmc   +1 more source

Negative Pressure Wound Therapy in an Immunocompromised Child: A Case Report From a Resource‐Limited Setting in Ghana

open access: yesClinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT An 8‐year‐old immunocompromised girl with a large septic wound on the left thigh was admitted to the facility after the failure of home treatment by the family. The child was generally stable aside from the difficulty in walking on the left leg.
Matilda Mawusi Kodjo   +5 more
wiley   +1 more source

Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 120-130, January 2026.
The investigational agent osivelotor, a small molecule hemoglobin (Hb) modifier in development for the treatment of sickle cell disease (SCD), acts by increasing Hb‐oxygen affinity and inhibiting the polymerization of sickle Hb. We report safety, pharmacokinetic (PK), and pharmacodynamic (PD) data from the first two phase 1 clinical trials of ...
Eleanor A. Lisbon   +15 more
wiley   +1 more source

Building a Comprehensive Sickle Cell Disease Program in Western Kenya: A Decade of Experience and Growth. [PDF]

open access: yesAnn Glob Health
Njuguna F   +18 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy